Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the 'Company') announced that at the 2025 European Society for Medical ...

My skin breaks out, my face is puffy, and my skin tone looks dull. And I'm not the only one. Just search TikTok: There are ...

Imdelltra combined with chemotherapy and PD-L1 therapy showed a 71% objective response rate and 82% disease control rate in ES-SCLC patients. The safety profile was manageable, with severe ...

Tarlatamab combined with chemoimmunotherapy achieved a 71% objective response rate in ES-SCLC, with a median response duration of 11 months. The safety profile was manageable, with grade 3 or 4 ...

This Breast Cancer Awareness Month, let’s pledge to stay informed, perform regular self-checks, encourage screenings, and ...

Fruquintinib plus sintilimab significantly improved PFS in advanced RCC patients compared to axitinib or everolimus, with a median PFS of 22.21 months versus 6.90 months. The combination therapy ...

Dr. Phone Fix Canada Corporation ("Dr. Phone Fix" or the "Company") announces that it has received approval from the TSX Venture Exchange (the "TSXV") to extend the deadline of its previously ...

Virtual Field, the company that invented virtual reality (VR) perimetry, today announced a major milestone: over 4 million ...

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint ...

The statements regarding Herpafend have not been evaluated by the Food and Drug Administration (FDA). This product is not ...

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies ...

Approval Broadens Indication for TEZSPIRE to a Second Disease Characterized by Epithelial-Driven Inflammation THOUSAND OAKS, Calif., Oct. 17, 2025 /PRNewswire/ -- ...